Advanced searches left 3/3
Search only database of 8 mil and more summaries

Vaccine Companies To Invest

Summarized by PlexPage
Last Updated: 02 July 2021

* If you want to update the article please login/register

General | Latest Info

Coronavirus fears have triggered volatility, corrections and ultimately a bear market in US stocks in 2020. Many companies have suffered massive price drops, but handful of stock picks have seen their prices hold up - and in some cases, even soar. One such cluster includes pharmaceutical companies and other health care stocks that are in race to develop COVID - 19 coronavirus vaccines and therapeutics. You can t overstate the stakes. As of March 11, there were 4. 7 million officially recorded coronavirus cases worldwide, causing more than 316, 000 deaths. The World Health Organization officially broke out pandemic designation, and governments across the world shut down mass gatherings of people to slow spread. Idea behind these moves? Buy time for pharmaceutical companies to come up with antivirals and vaccines. Dozens of Big Pharma and small biotechnology companies alike are already involved in COVID - 19 coronavirus treatment and vaccine development. But other health care stocks are rising to challenge, too: makers of diagnostic test kits, sanitizers and protective masks are all ramping up to meet unprecedented demand. Here are 10 health and pharmaceutical companies playing role in the fight to control COVID - 19 coronavirus, including several updates to reflect some treatments progress. Each of these stocks has potential for considerable gain, whether it's because they re developing treatment or their products are in greater need amid outbreak. To date, each stock has outperformed the S & P 500 since the bear market began in mid - February, with many posting healthy To downright gaudy gains. Market value: 24. 8 billion Performance since market peak: + 252. 5 % Moderna is a major player in the race to develop coronavirus Vaccine, and at the moment, it might be the most exciting name in space. In late February, biotechnology company began shipping batches of its development - stage COVID - 19 Vaccine For use in Phase 1 Human trials to the National Institutes of Health. Moderna turned around this first vaccine batch in just 42 days, and it started recruiting human trial participants in March. Early May 18, Moderna Report that its vaccine created COVID - 19 antibodies in each of 45 participants of Phase 1 trial, and that it created neutralizing antibodies in at least eight participants. That news sent both MRNA shares and the broader market skyrocketing in premarket trading. Moderna now expects to conduct a Phase 3 trial in July. In addition to its coronavirus Vaccine candidate, Moderna has vaccines in development for Zika virus, Respiratory infections, Epstein - Barr, chikungunya and several types of cancer. In all, company has 24 drug candidates in its pipeline, including 12 in clinical studies, and is partner with AstraZeneca, Merck and various US government agencies. Moderna's Vaccine For congenital cytomegalovirus, leading cause of birth defects, is its most advanced product and is expected to enter Phase 3 clinical trials this year. Moderna recently raised 500 million through public offering and has access to more than 2 billion to invest in its research programs. The Company is not yet profitable given lack of marketed products.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Oxford University/AstraZeneca

Scientists are getting closer to developing vaccine for Covid - 19. Success would be a game - changer and mark a key turning point in the fight against virus. Investors are betting it would be a boon for winning company as governments around world would immediately clamber to place orders. Moderna, biotechnology company based in America, is leading the race, according to Nina Deka of Robo Global, Research Group. Its share price has risen by 170pc this year but has been very volatile. Larger, more diversified companies carry less risk, according to Dan Mahony of Polar Capital, investment manager. They include Pfizer, which has deal with BioNTech, German biotech company; Johnson & Johnson, whose vaccine programme is nearing clinical trials; AstraZeneca, which has partnership with Oxford University and expects to announce trial results in June; and GlaxoSmithKline, which is working with Sanofi, French company. However, healthcare analysts say it is foolish to chase Vaccine because risks outweigh rewards for investors. Ms Deka say attempting to find a winning company does not make sense as there were so many firms in fold. This translates to a great deal of information to pick through. Most people dont have that kind of bandwidth, she say. Even finding a vaccine would not necessarily translate into profits, according to Mr Mahony. He said news that division of Americas Department of Health had announced 820m funding agreement with Oxford University and AstraZeneca meant that government involvement would curtail profits. During a pandemic, any vaccine is likely to be sold at cost because manufacturing scale - up need will require significant funding from governments around the world, says Mr Mahony. He argued that in the longer term most significant implication for investors was that the drug industry had stepped up at a time when the world needed it. This would help firms in debate about drug pricing and boost future profits, he say.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Moderna and Pfizer/BioNTech

Cramer said that second place in the survey was tie between Moderna and a joint effort from Pfizer and biotech firm BioNTech. They receive 19 votes apiece, he say. Of the three stocks, Cramer said he favor Pfizer, New York - base drugmaker. Its stock closed Thursday's session at 38. 41 and is down nearly 2 % so far in 2020. Pfizer has a portfolio of decent, albeit boring, drugs, and while there's nothing huge in the pipeline, companies get very deep pockets, so if their vaccine doesn t win, they can always make some very exciting acquisitions, Cramer say. By contrast, Cramer say that Pfizer's partner in the vaccine effort, BioNTech, has less upside potential if attempts to produce an effective vaccine for COVID - 19 are unsuccessful. Shares of a German biotech firm closed down 15 % on Thursday at 88. 51 per share. Its stock has run up more than 160 % this year. Biontech's stock is too binary for me. They don t have enough other shots on goal, Cramer say, one day after both firms announced they had nearly 2 billion agreement with the US government if the vaccine proves effective. Cramer say he used to be a fan of Moderna, citing its use of artificial intelligence in its development practices. But recently, he say, he has started to sour on Cambridge, Massachusetts - base firm. Valuation is also a concern, he add. I think Moderna's become too promotional, too quick to praise its own work off very small sample size, which is odd because they ve never actually produced vaccine before, he say. Now I do love this stock in their 20s and 30s and 40s and even in their 50s, but up here at 75?. I now say, no, thank you.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

J&J, Novavax and Sanofi/GlaxoSmithKline

The biotechnology industry includes companies that develop drugs and diagnostic compounds for treatment of diseases and medical conditions. These products must go through a rigorous, costly, and time - consuming testing process before potentially obtaining approval from the US Food and Drug Administration. This means that investors may wait for years before knowing whether drugs under development will pay off. Group include small start - Up companies that focus on single drugs as well as large, well - establish corporations that generate dozens of potential new drugs each year. Some of the largest biotechnology companies in the world include Amgen Inc., Regeneron Pharmaceuticals Inc., And Biogen Inc. Many biotech companies have been rushing to develop tests and treatments for COVID - 19. During the past year, biotech stocks, as represented by iShares NASDAQ Biotechnology ETF, have posted a total return of 22. 3 % compared to Russell 1000's total return of 13. 8 % as of September 11, 2020. All data below is as of September 14, 2020. Here are the top 3 biotech stocks with the best value, fastest earnings growth, and most momentum.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Bottom line

The race to develop a vaccine for Covid - 19 is not a zero - sum game, Cramer say. It is possible that multiple companies develop successful vaccines, he say. For investors, Johnson & Johnson is the best place to look right now among vaccine candidates, he say. He added that he also like Regeneron, for both its potential Covid - 19 treatment and its other line of products. On the other hand, Cramer say investors should sell Inovio Pharmaceuticals, shares of which are up more than 600 % this year, based on feedback from expert survey. If you want to make informed wager or at least invest in vaccine stocks, I think AstraZeneca has most promising formulation, he say. However, J & J has best stock, because it's inexpensive and it's gets so much else going if it turns out to be loser in Covid - 19 vaccine race for cure or, at least, immunity.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Article content

Dozens of biotech and healthcare companies have entered the race to produce successful treatment or cure for COVID - 19 since March, when a pandemic swept through North America. Some of the entrants are blue - chip names such as Johnson & Johnson and Merck & Co Inc., While others are smaller competitors trading on TSX Venture Exchange. But only a few names have captured the interest of investors thanks to returns tripling or to positive news from trials pushing the entire S & P 500 forward. Here look at five of those stocks. Gilead was the first of these stocks to draw the attention of mainstream investor,sss even if its gains are least impressive of the five. Year to date, stocks have rallied little more than 15 per cent. But at its peak, that rally hit 30 per cent and Gilead was demonstrating power to move the entire market on good or bad news. Its antiviral drug, Remdesivir, was used to treat Ebola patients and has now been repurposed to reduce recovery time for COVID - 19. Drug has already been approved by the FDA for use in US, according to Oppenheimer analyst Hartaj Singh. Despite this success, stock has been lagging for one major reason: People are struggling to understand how theyre going to monetize, Singh say. While it may seem like stocks rally is do, Singh warns against making that assumption. Closing Monday at US 76. 97, it still has room to run to his US 90 price target.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Pharma vulnerable to stock volatility

Pharmaceutical stocks remain popular with investors, and rightly so, thanks to their long - term revenues and excellent dividend yields, says Chris Beauchamp, chief market analyst at trading company IG. In a world where yield is even harder to come by, such stocks will maintain their place at the top of watch lists. Yet the trial - and - error nature of vaccine development exposes pharmaceutical companies to volatility in stock market. Modernas share price dropped nearly 11 per cent in mid - May following reports people were experiencing adverse reactions to its vaccine candidate. Gilead Sciences stock, meanwhile, fell after the announcement that a large trial of its drug Remdesivir had shown only limited benefit to patients it had been tested on. Investing in pharmaceuticals can be risky and it is difficult to predict which company will eventually produce the best outcome, says Sheena Berry, healthcare analyst at Quilter Cheviot Investment Management. Share prices can rise or fall extremely quickly on even smallest of rumours; Gileads stock has oscillated throughout past few months. Igs senior analyst Josh Mahony say caution is require. He argue that given volatility around Gilead and Moderna, traders should be jumping to invest in pharmaceutical company. Experts seem to indicate that vaccine is going to take some time to develop, yet markets can treat each trial announcement as if we are on the cusp of a huge breakthrough, he add.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

COVID accelerating ESG investment

Ensuring access to drugs and medicines is critical. Most of world pharmaceutical companies have resources and capital dedicated to addressing healthcare challenges And pandemic will have only reinforce their position. If traders and investors are looking for stocks with conscience, then those in the race to develop the COVID - 19 Vaccine could be right play. The pandemic is an accelerating trend towards ESG stocks, so call because they meet certain environmental, social and governance criteria. And although there are risks involve, for example possibility of product recalls or lack of access to vaccines in developing countries with poor healthcare system,sss candidates in the race to develop vaccines are likely to benefit from ESG investing. Investment strategies that integrate ESG have gained traction in recent years. Investors have become much more aware of how vulnerable our ecosystem is, says Berry. And coronavirus has emphasise just how vulnerable we all are.


Table 1

No CONTENT OR ANY part thereof may BE modify, reverse engineer, reproduced OR distributed in ANY form by ANY means, OR stored in database OR retrieval system, without prior write permission OF Standard & Poors Financial Services LLC OR its affiliates. Content shall NOT BE USE FOR ANY unlawful OR unauthorized purposes. S & P AND ANY third - party providers, as well as their directors, officers, shareholders, employees OR agents do NOT guarantee accuracy, completeness, timeliness OR availability OF CONTENT. S & P PARTIES are NOT responsible FOR ANY ERRORS OR omissions, regardless OF cause, FOR results obtained FROM USE OF CONTENT, OR FOR security OR maintenance OF ANY data input by user. Content is provided on an as is basis. S & P PARTIES DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING, BUT NOT LIMITED TO, ANY WARRANTIES OF MERCHANTABILITY OR FITNESS FOR PARTICULAR PURPOSE OR USE, FREEDOM FROM BUGS, SOFTWARE ERRORS OR DEFECTS, THAT CONTENTS FUNCTIONING WILL BE UNINTERRUPTED OR THAT CONTENT WILL OPERATE WITH ANY SOFTWARE OR HARDWARE CONFIGURATION. In no event shall S & P PARTIES BE liable TO ANY party FOR ANY direct, indirect, incidental, exemplary, compensatory, punitive, special OR consequential damages, costs, expenses, legal fees, OR losses in connection WITH ANY USE OF CONTENT even if advised OF possibility OF such damages. Credit - relate AND other analyses, INCLUDING Ratings, AND statements in CONTENT are statements OF opinion as OF date they are EXPRESS AND NOT statements OF fact. S & Ps opinions, analyses AND rating acknowledgment decisions are NOT recommendations TO purchase, hold, OR sell ANY securities OR TO make ANY investment decisions, AND do NOT address suitability OF ANY security. S & P assume no obligation TO update CONTENT following publication in ANY form OR format. Content should NOT BE relied on AND is NOT a substitute FOR skill, judgment AND experience OF user, its management, employees, advisors AND / OR clients when making investments AND other business decisions. S & P do NOT act as fiduciary OR investment advisor except where registered as such. While S & P has obtained information FROM sources it believes TO BE reliable, S & P does NOT perform audits AND undertakes no duty OF due diligence OR independent verification OF ANY information it receive. Rating - related publications may BE published FOR a variety OF reasons THAT are NOT necessarily dependent on action by rating committees, INCLUDING, BUT NOT LIMITED TO, publication OF periodic update on credit rating AND related analyses. To the extent THAT regulatory authorities allow rating agency TO acknowledge in one jurisdiction rating issue in another jurisdiction FOR certain regulatory purposes, S & P reserves the right TO assign, withdraw OR suspend such acknowledgment at ANY time AND in its sole discretion. S & P PARTIES DISCLAIM ANY duty whatsoever arising out OF assignment, withdrawal OR suspension OF acknowledgment as well as ANY liability FOR ANY damage alleged TO have been suffered on account thereof.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

Sources

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions.

* Please keep in mind that all text is machine-generated, we do not bear any responsibility, and you should always get advice from professionals before taking any actions

logo

Plex.page is an Online Knowledge, where all the summaries are written by a machine. We aim to collect all the knowledge the World Wide Web has to offer.

Partners:
Nvidia inception logo

© All rights reserved
2021 made by Algoritmi Vision Inc.

If you believe that any of the summaries on our website lead to misinformation, don't hesitate to contact us. We will immediately review it and remove the summaries if necessary.

If your domain is listed as one of the sources on any summary, you can consider participating in the "Online Knowledge" program, if you want to proceed, please follow these instructions to apply.
However, if you still want us to remove all links leading to your domain from Plex.page and never use your website as a source, please follow these instructions.